Fig. 1 · Structure

Documents & Downloads

Alendronate sodium hydrate

Cat. No. A10050 CAS 121268-17-5
Alendronate is a nitrogen-containing bisphosphonate that is commonly used in the treatment of osteoporosis and other metabolic bone diseases.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
Lewis lung carcinoma cell line IC50 0.43 μM Cytotoxicity against mouse LLC cells after 24 hrs by resazurin assay [PMID: 21536448]
Lewis lung carcinoma cell line IC50 2.62 μM Cytotoxicity against mouse LLC cells after 72 hrs by resazurin assay [PMID: 21536448]

Alendronate sodium hydrate Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Alendronate sodium hydrate from 1 published reference.

Alendronate sodium hydrate In Vitro Studies

Alendronate impaired protein prenylation in RAW 264.7-derived osteoclasts. Loss of Atraid attenuated this response and alendronate-induced apoptosis, identifying ATRAID as a determinant of cellular sensitivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

ATRAID-dependent osteoclast responses

Cell-based study · Wild-type and Atraid-knockout RAW 264.7 cells differentiated into osteoclasts [1]

Alendronate-induced apoptosis and disruption of protein prenylation were attenuated by Atraid loss.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Annexin V-positive cells after 48 hQualitative response Atraid deficiency conferred resistance to alendronate-induced apoptosis.[1]
Unprenylated Rap1a after 48 hQualitative response Atraid-knockout cells resisted alendronate-induced inhibition of prenylation.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Annexin V assay: 0, 30 μM, 80 μM. Prenylation assay: 0, 20 μM, 80 μM.
Exposure duration
48 hours
Method
Cell-culture exposure; wild-type and Atraid-knockout comparisons, including 0 μM controls.
Reported limits
Vehicle and exact salt/hydration not established in retrieved main text; supplementary methods and figure images not retrieved. Numerical response magnitudes not extracted.
Methods and source locations

Compound reported in the paper: Alendronate; Compound label in the paper: ALN

Alendronate active-moiety effects in the stated models; no hydrate-specific potency or mass-dose conversion.

Results, ATRAID is required cell-autonomously for N-BP inhibition of osteoclast function; Fig. 3E–F legend (BioC passages 24, 131)

Annexin V-positive cells after 48 h: Flow cytometry; 0, 30 μM, 80 μM alendronate; n=3 biological experiments; legend reports mean with standard deviation. — Results, ATRAID is required cell-autonomously for N-BP inhibition of osteoclast function; Fig. 3E–F legend (BioC passages 24, 131)

Unprenylated Rap1a after 48 h: Immunoblot; 0, 20 μM, 80 μM alendronate; Gapdh loading control. No band intensities estimated. — Results, ATRAID is required cell-autonomously for N-BP inhibition of osteoclast function; Fig. 3E–F legend (BioC passages 24, 131)

Alendronate sodium hydrate In Vivo Studies

In ovariectomized female mice, alendronate treatment increased femoral structural and mechanical measures in wild-type animals, with weaker responses in global Atraid-knockout mice. The global knockout design limits assignment of the in vivo effect to a particular cell type. [1]

Bone response in ovariectomized mice

Animal study · 3.5-month-old female wild-type and global Atraid-knockout mice; ovariectomy with sham-operated controls [1]

Alendronate increased femoral structural and mechanical measures in wild-type ovariectomized mice; responses were blunted in Atraid-knockout mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Femoral cortical thickness and area, trabecular bone volume fraction and thickness; stiffness and yield loadQualitative response Increased in treated wild-type ovariectomized mice; effects blunted in Atraid-knockout mice.[1]

Conditions shared by the study groups

Frequency
Weekly dose basis reported as μg/kg/week; injection schedule not independently established.
Treatment course
Four weeks, starting concurrently with surgery
Vehicle
Saline comparator; drug formulation details not retrieved.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Alendronate versus saline, by genotype
100 μg/kg/week
Saline-treated ovariectomized mice within each genotype; sham-operated groups also included.Femoral structure and strength improved in wild-type mice, with blunted responses after global Atraid deletion.[1]
Alendronate versus saline, by genotype
Model: Wild-type and global Atraid-knockout ovariectomized female mice
Reported limits: Route, exact formulation and dose mass basis (salt versus active moiety) not established; no conversion made.
Methods and source locations

Compound reported in the paper: Alendronate; Compound label in the paper: ALN

Alendronate active-moiety effects in the stated models; no hydrate-specific potency or mass-dose conversion.

Results, ATRAID is required for organismal responses; Fig. 2A–H legend; Study design and Statistical analysis (BioC passages 15–18, 36, 38, 129); Discussion limitation, BioC passage 33

Femoral cortical thickness and area, trabecular bone volume fraction and thickness; stiffness and yield load: Micro-CT and three-point bending; n=6–11 mice per group. Numerical effect sizes not extracted. — Results, ATRAID is required for organismal responses; Fig. 2A–H legend; Study design and Statistical analysis (BioC passages 15–18, 36, 38, 129); Discussion limitation, BioC passage 33

Alendronate versus saline, by genotype · Results, ATRAID is required for organismal responses; Fig. 2A–H legend; Study design and Statistical analysis (BioC passages 15–18, 36, 38, 129); Discussion limitation, BioC passage 33

Specifications

Manufacturer Adooq Bioscience
CAS Number 121268-17-5
Formula C4H12NO7P2.H6NaO3
Molecular Weight 325.1
Synonyms MK-217,G-704650; Fosamax; Adronat
SMILES
C(CC(O)(P(=O)(O)O)P(=O)(O)[O-])CN.O.O.O.[Na+]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water Warmed: 19 mg/mL (58.25 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Alendronate sodium hydrate Research References

  1. [1] Surface LE, Burrow DT, Li J, et al. ATRAID regulates the action of nitrogen-containing bisphosphonates on bone. Science Translational Medicine (2020). PMID: 32434850 DOI: 10.1126/scitranslmed.aav9166 Source material

Added to your cart

View Cart Checkout
Loading...